Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high.

Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusions needed to one per month.

After hours: March 12 at 7:52:40 PM EDT Loading Chart for PKG ...

Ravensburg, Germany, March 11, 2025 – Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), announces a significant expansion of its pharmaceutical materials ...

Lombardy ranks among Europe’s top pharma manufacturers, with Milano leading in API production, automated manufacturing, packaging, and regulatory services. Our renowned research centers and hospitals ...

Health care systems that adopted a higher volume of telehealth services less frequently used several low-value screening and diagnostic tests, according to results of a cohort study published in ...